{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:32Z","timestamp":1793316572124,"version":"4.5.0"},"reference-count":82,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56bright natural killer (NK) cells. Furthermore, there appears to be a direct correlation between CD56bright NK cell expansion and DAC HYP efficacy in reducing relapses and MRI evidence of disease activity in patients with RMS in phase II and phase III double-blind, placebo- and active comparator-controlled trials. Therapeutic efficacy was maintained during open-label extension studies. However, treatment was associated with an increased risk of rare adverse events, including cutaneous inflammation, autoimmune hepatitis, central nervous system Drug Reaction with Eosinophilia Systemic Symptoms (DRESS) syndrome, and autoimmune Glial Fibrillary Acidic Protein (GFAP) alpha immunoglobulin-associated encephalitis. As a result, DAC HYP was removed from clinical use in 2018. The lingering importance of DAC is that its use led to a deeper understanding of the underappreciated role of innate immunity in the potential treatment of autoimmune disease.<\/jats:p>","DOI":"10.3390\/biomedicines7010018","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T03:49:31Z","timestamp":1552362571000},"page":"18","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis"],"prefix":"10.3390","volume":"7","author":[{"given":"Stanley","family":"Cohan","sequence":"first","affiliation":[{"name":"Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lucassen","sequence":"additional","affiliation":[{"name":"Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Romba","sequence":"additional","affiliation":[{"name":"Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9789-4113","authenticated-orcid":false,"given":"Stefanie","family":"Linch","sequence":"additional","affiliation":[{"name":"Providence Health and Services, Regional Research Department, Portland, OR 97213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V72.5.1805.1805","article-title":"Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2","volume":"72","author":"Waldmann","year":"1988","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group","volume":"338","author":"Vincenti","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00007890-200109150-00017","article-title":"Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1474-4422(14)70039-0","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial","volume":"13","author":"Giovannoni","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/353858a0","article-title":"Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis","volume":"353","author":"Lenardo","year":"1991","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/01.TP.0000063937.53702.97","article-title":"Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation","volume":"75","author":"Baan","year":"2003","journal-title":"Transplantation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13311-012-0147-4","article-title":"Daclizumab therapy for multiple sclerosis","volume":"10","author":"Bielekova","year":"2013","journal-title":"Neurotherapeutics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-3083.2009.02281.x","article-title":"CD25 blockade protects T cells from activation-induced cell death (AICD) via maintenance of TOSO expression","volume":"70","author":"Richter","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.288.5466.675","article-title":"Control of homeostasis of CD8+ memory T cells by opposing cytokines","volume":"288","author":"Ku","year":"2000","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.immunol.17.1.221","article-title":"Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment","volume":"17","author":"Lenardo","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/83253","article-title":"IL-15 and IL-2: A matter of life and death for T cells in vivo","volume":"7","author":"Li","year":"2001","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.4049\/jimmunol.170.10.5075","article-title":"Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming","volume":"170","author":"Granucci","year":"2003","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1146\/annurev.bi.58.070189.004303","article-title":"The multi-subunit interleukin-2 receptor","volume":"58","author":"Waldmann","year":"1989","journal-title":"Annu. Rev. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy","volume":"17","author":"Wuest","year":"2011","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1073\/pnas.91.8.3344","article-title":"Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits","volume":"91","author":"Roessler","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.1631559","article-title":"Cloning of the gamma chain of the human IL-2 receptor","volume":"257","author":"Takeshita","year":"1992","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/cyto.2001.0862","article-title":"Signaling domains of the interleukin 2 receptor","volume":"14","author":"Gaffen","year":"2001","journal-title":"Cytokine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12860","DOI":"10.1016\/S0021-9258(18)37640-3","article-title":"Down-regulation of high affinity interleukin 2 receptors in a human tumor T cell line. Interleukin 2 increases the rate of surface receptor decay","volume":"263","author":"Duprez","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4049\/jimmunol.137.5.1552","article-title":"High- and low-affinity interleukin 2 receptors: Distinctive effects of monoclonal antibodies","volume":"137","author":"Fujii","year":"1986","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22044","DOI":"10.1074\/jbc.273.34.22044","article-title":"Endocytosis of the common cytokine receptor gammac chain. Identification of sequences involved in internalization and degradation","volume":"273","author":"Morelon","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1083\/jcb.129.1.55","article-title":"Endocytosis of interleukin 2 receptors in human T lymphocytes: Distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains","volume":"129","author":"Hemar","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4049\/jimmunol.166.3.1675","article-title":"Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells","volume":"166","author":"Malek","year":"2001","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.immuni.2005.01.013","article-title":"A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells","volume":"22","author":"Freud","year":"2005","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev-immunol-020711-075053","article-title":"Innate lymphoid cells: Emerging insights in development, lineage relationships, and function","volume":"30","author":"Spits","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.1962","article-title":"The expanding family of innate lymphoid cells: Regulators and effectors of immunity and tissue remodeling","volume":"12","author":"Spits","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3389\/fimmu.2017.01569","article-title":"Shaping Innate Lymphoid Cell Diversity","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/acn3.181","article-title":"Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis","volume":"2","author":"Lin","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145ra106","DOI":"10.1126\/scitranslmed.3004140","article-title":"Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis","volume":"4","author":"Perry","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.4049\/jimmunol.0902238","article-title":"An IL-2 paradox: Blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells","volume":"185","author":"Martin","year":"2010","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jneuroim.2005.02.011","article-title":"Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis","volume":"163","author":"Xu","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_39","first-page":"657","article-title":"Dysfunction of natural killer cells in multiple sclerosis: A possible pathogenetic factor","volume":"39","author":"Benczur","year":"1980","journal-title":"Clin. Exp. Immunol."},{"key":"ref_40","first-page":"419","article-title":"Decreased NK killing in patients with multiple sclerosis: An analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity in the disease","volume":"47","author":"Merrill","year":"1982","journal-title":"Clin. Exp. Immunol."},{"key":"ref_41","first-page":"11","article-title":"Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis","volume":"49","author":"Neighbour","year":"1982","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1212\/WNL.38.11.1739","article-title":"Multiple sclerosis: In relapsing patients, immune functions vary with disease activity as assessed by MRI","volume":"38","author":"Oger","year":"1988","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archneurol.2009.50","article-title":"Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis","volume":"66","author":"Bielekova","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1212\/NXI.0000000000000065","article-title":"CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS","volume":"2","author":"Elkins","year":"2015","journal-title":"Neurol. NeuroImmunol. Neuroinflamm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archneurol.2009.16","article-title":"Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis","volume":"66","author":"Oh","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1402140","article-title":"In vivo maintenance of human regulatory T cells during CD25 blockade","volume":"194","author":"Huss","year":"2015","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/bcp.13051","article-title":"Population PK-PD analyses of CD25 occupancy, CD56(bright) NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis","volume":"82","author":"Diao","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"134ra162","DOI":"10.1126\/scitranslmed.3003330","article-title":"CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients","volume":"4","author":"Rech","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1203\/00006450-200007000-00004","article-title":"Human IL-2 receptor alpha chain deficiency","volume":"48","author":"Roifman","year":"2000","journal-title":"Pediatr. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1073\/pnas.94.7.3168","article-title":"Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor","volume":"94","author":"Sharfe","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1172\/JCI6218","article-title":"Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy","volume":"106","author":"Fehniger","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/1352458511414755","article-title":"Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis","volume":"17","author":"Sheridan","year":"2011","journal-title":"Mult. Scler."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2016.03.008","article-title":"Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy","volume":"294","author":"Gillard","year":"2016","journal-title":"J. NeuroImmunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.1194597","article-title":"Lineage relationship analysis of RORgammat+ innate lymphoid cells","volume":"330","author":"Sawa","year":"2010","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1189\/jlb.1007712","article-title":"Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells","volume":"84","author":"Mnasria","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-014-0159-9","article-title":"Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: Integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration","volume":"53","author":"Othman","year":"2014","journal-title":"Clin. Pharm."},{"key":"ref_60","first-page":"9","article-title":"Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis","volume":"8","author":"Tran","year":"2016","journal-title":"Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1352458513494488","article-title":"Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis","volume":"20","author":"Zhang","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ane.12712","article-title":"Safety concerns and risk management of multiple sclerosis therapies","volume":"136","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.0402653101","article-title":"Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta","volume":"101","author":"Bielekova","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/01.wnl.0000267662.41734.1f","article-title":"Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results","volume":"69","author":"Rose","year":"2007","journal-title":"Neurology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/1352458517707345","article-title":"Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study","volume":"24","author":"Benedict","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gold, R., Radue, E.W., Giovannoni, G., Selmaj, K., Havrdova, E., Stefoski, D., Sprenger, T., Montalban, X., Cohan, S., and Umans, K. (2016). Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol., 16.","DOI":"10.1186\/s12883-016-0635-y"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1212\/WNL.0000000000002417","article-title":"Cutaneous adverse events in multiple sclerosis patients treated with daclizumab","volume":"86","author":"Cortese","year":"2016","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2009.02180.x","article-title":"In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases","volume":"65","author":"Zawodniak","year":"2010","journal-title":"Allergy"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Porebski, G. (2017). In Vitro Assays in Severe Cutaneous Adverse Drug Reactions: Are They Still Research Tools or Diagnostic Tests Already?. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081737"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice","volume":"5","author":"Peter","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1212\/NXI.0000000000000479","article-title":"Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS","volume":"5","author":"Scheibe","year":"2018","journal-title":"Neurol. NeuroImmunol. Neuroinflamm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1177392818785136","DOI":"10.1177\/1177392818785136","article-title":"DRESS Syndrome and Daclizumab Failure-Were Potentially Dangerous Signs Missed in Clinical Trials?","volume":"12","author":"Avasarala","year":"2018","journal-title":"Drug Target. Insights"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Molofsky","year":"2014","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAPalpha IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol. NeuroImmunol. Neuroinflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"(2008). Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. N. Engl. J. Med., 359, 1786\u20131801.","DOI":"10.1056\/NEJMoa0802670"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","article-title":"Natalizumab treatment for multiple sclerosis: Recommendations for patient selection and monitoring","volume":"6","author":"Kappos","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_80","first-page":"261","article-title":"Fingolimod for multiple sclerosis and emerging indications: Appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/7\/1\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:37:52Z","timestamp":1760186272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/7\/1\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["biomedicines7010018"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines7010018","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]}}}